Q-omics provides the consensus-scored LINC00677 profile across patient tissues and cancer cell-line models. LINC00677 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC00677 is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, LINC00677 RNA expression shows 14,158 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, STAD, and THYM as cancer lineages where LINC00677 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00677 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00677 survival associations across molecular data types. LINC00677 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00677 RNA expression–survival associations across cancer types. High LINC00677 expression shows unfavorable associations in KIRC, LGG and BRCA, but favorable associations in BLCA, HNSC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC00677 RNA expression.
This table summarizes LINC00677 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00677. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00677 shows lower tumor expression in KICH and COAD and higher tumor expression in STAD, THCA, UCEC and HNSC. The STAD box plot shows higher LINC00677 RNA expression in tumor versus normal tissue (log2 FC = +0.362, t-test p < 0.001).
This table shows molecular features associated with LINC00677 in patient tissues and cancer cell lines. In patient samples, LINC00677 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
